Pfizer (NYSE:PFE) Trading 1.2% Higher - What's Next?

Pfizer Inc. (NYSE:PFE - Get Free Report) shares traded up 1.2% during trading on Monday . The stock traded as high as $23.29 and last traded at $23.19. 18,632,806 shares changed hands during trading, a decline of 54% from the average session volume of 40,447,109 shares. The stock had previously closed at $22.92.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a report on Monday, March 10th. UBS Group boosted their price target on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday. Citigroup reissued a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Finally, Cantor Fitzgerald started coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price target for the company. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, five have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $29.64.

Pfizer Stock Up 2.6 %

The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The business's fifty day moving average price is $24.44 and its 200 day moving average price is $25.85. The firm has a market capitalization of $138.44 billion, a PE ratio of 17.31, a PEG ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The company had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm's revenue for the quarter was down 7.8% on a year-over-year basis. During the same period last year, the firm earned $0.82 EPS. On average, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be issued a $0.43 dividend. The ex-dividend date is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.05%. Pfizer's dividend payout ratio is presently 121.99%.

Insider Buying and Selling

In other news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.06% of the company's stock.

Institutional Investors Weigh In On Pfizer

Large investors have recently added to or reduced their stakes in the business. Retirement Wealth Solutions LLC acquired a new position in shares of Pfizer in the fourth quarter worth $26,000. Rialto Wealth Management LLC purchased a new stake in Pfizer during the 4th quarter worth about $26,000. Clarity Asset Management Inc. acquired a new position in Pfizer in the 4th quarter valued at about $27,000. Gould Capital LLC lifted its holdings in Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares in the last quarter. Finally, Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Pfizer during the 4th quarter worth about $28,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.